Diagnostically, RNF43 mutations occur in early-stage gastric lesions [220], which could be used to stratify patients who may benefit from compounds that block the secretion of Wnt ligands, which have substantial efficacy in other ‘Wnt-addicted’ RNF43 mutant cancers [221,222]. Here, RNF43 is linked to cancer.